Products - Eye conditions | Topic

Showing 16 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
23 July 2025
Expected publication date:
13 August 2025
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 January 2026
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegcetacoplan for treating geographic atrophy [ID4041]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Eye conditions Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 16 products

Teprotumumab for treating thyroid eye disease [ID6432]

Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]

Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]

Abicipar pegol for treating wet age-related macular degeneration [ID1533]

Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

Aflibercept for untreated diabetic macular oedema [TSID10621]

Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]

Pegcetacoplan for treating geographic atrophy [ID4041]

Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]

NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Eye conditions Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 16 products

Product type
1 selected

New and updated
1 selected